Loading...
•
Dec 31, 2023
Arbutus Q4 2023 Earnings Report
Arbutus reported its fourth quarter and year-end financial results, providing a corporate update.
Key Takeaways
Arbutus Biopharma reported its Q4 and year-end 2023 financial results, highlighting key clinical data expected in 2024 and a strong financial position with $132M in cash and investments.
On track to report key clinical data in 2024 from two ongoing Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101.
Plans to initiate a third Phase 2a clinical trial with imdusiran in the first half of 2024.
Claim Construction for Moderna LNP litigation occurred on February 8, 2024; trial date set for April 21, 2025.
Strong financial position with cash and investments of $132M; cash runway into Q1 2026.
Revenue by Segment
Forward Guidance
Arbutus expects its 2024 net cash burn to range from between $63 million to $67 million, excluding any proceeds received from its “at the market” offering program. The Company believes its cash, cash equivalents and investments in marketable securities of $132.3 million as of December 31, 2023, are sufficient to fund its operations into the first quarter of 2026.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...